A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial
暂无分享,去创建一个
[1] D. Schoenfeld,et al. Graphing the Win Ratio and its components over time , 2018, Statistics in medicine.
[2] Pamela A Shaw,et al. Use of composite outcomes to assess risk–benefit in clinical trials , 2018, Clinical trials.
[3] S. Solomon,et al. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials , 2018, Circulation.
[4] S. Pocock,et al. The Primary Outcome Is Positive - Is That Good Enough? , 2016, The New England journal of medicine.
[5] D. Oakes. On the win-ratio statistic in clinical trials with multiple types of event , 2016 .
[6] M. Vandemeulebroecke,et al. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components , 2016, Pharmaceutical statistics.
[7] P. Parfrey,et al. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. , 2016, Contemporary clinical trials.
[8] M Buyse,et al. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] P. Armstrong,et al. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials , 2015, Statistical methods in medical research.
[10] P. Armstrong,et al. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. , 2015, European heart journal.
[11] W. Brannath,et al. Opportunities and challenges of combined effect measures based on prioritized outcomes , 2014, Statistics in medicine.
[12] J. Cutler,et al. Multiple Risk Factor Intervention Trial Revisited: A New Perspective Based on Nonfatal and Fatal Composite Endpoints, Coronary and Cardiovascular, During the Trial , 2012, Journal of the American Heart Association.
[13] C. Meinert. Clinical Trials Dictionary: Terminology and Usage Recommendations, Second Edition , 2012 .
[14] S. Pocock,et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities , 2011, European heart journal.
[15] J. Saver,et al. Weighting Components of Composite End Points in Clinical Trials: An Approach Using Disability-Adjusted Life-Years , 2011, Stroke.
[16] K. Zou,et al. Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power. , 2010, Journal of clinical epidemiology.
[17] Lisa M. Schwartz,et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review , 2010, BMJ : British Medical Journal.
[18] D. Altman,et al. Composite Outcomes in Cardiovascular Research: A Survey of Randomized Trials , 2008, Annals of Internal Medicine.
[19] Daniel J Sargent,et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Gordon H Guyatt,et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.
[21] Gerry Gray,et al. Key issues in end point selection for heart failure trials: composite end points. , 2005, Journal of cardiac failure.
[22] G. Guyatt,et al. Validity of composite end points in clinical trials , 2005, BMJ : British Medical Journal.
[23] Avis J. Thomas,et al. Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial , 2004, Clinical trials.
[24] Nick Freemantle,et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? , 2003, JAMA.
[25] J. Hodges,et al. Rule-based ranking schemes for antiretroviral trials. , 1997, Statistics in Medicine.
[26] M D Hughes,et al. Power considerations for clinical trials using multivariate time-to-event data. , 1997, Statistics in medicine.
[27] A. Gotto. The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. , 1997, JAMA.
[28] J. Neaton,et al. Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). , 1994, Statistics in medicine.
[29] W. Weaver,et al. A method of assigning scores to the components of a composite outcome: an example from the MITI trial. , 1992, Controlled clinical trials.
[30] D. Spodick. Multiple risk factor intervention trial. , 1985, The American journal of cardiology.
[31] J. Lachin,et al. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. , 2016, Biostatistics.
[32] C. Meinert. Clinical Trials Dictionary: Terminology and Usage Recommendations , 1996 .
[33] J. Cutler,et al. The use of subjective rankings in clinical trials with an application to cardiovascular disease. , 1992, Statistics in medicine.
[34] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[35] L. J. Wei,et al. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .